AUSA 2022: UVision accelerates opening of new US production and training centre
Higher-than-expected demand for Hero loitering munitions prompted the US subsidiary of UVision Air to bring forward the opening of its new production facility to 6 October.
‘The opening of the facility signifies the company’s increased commitment to the US market,’ UVision claimed.
Maj Gen (ret) Avi Mizrachi, CEO of UVision, said: ‘Following the signing of our latest contract with a Latin American country and the growing demand for roving armament systems around the world, we decided to bring forward the opening of our new production plant in Virginia.’
The 25,000ft2 (2,320m2) factory in Quantico is operated by UVision USA Corporation.
More from Defence Notes
-
US lawmakers warn that “more military spending is absolutely necessary” to ensure Pentagon’s readiness
The US Congress has raised concerns about how inflation rates and cuts in main acquisition programmes could affect the US military.
-
Can the US overcome Russian and Chinese nuclear capabilities?
Washington’s ageing inventory and the pace Moscow and Beijing have been modernising their capabilities put in check the US Nuclear deterrence.
-
US FY2024 funding package passes as China closes military capability gap
The Pentagon has been operating under temporary funding since October 2023, which has impacted its main acquisition and development programmes, increasing the capability gap between the US and China.
-
NATO outlines future challenges as Ukrainian funding from US stalls
In 2023, defence spending increased by an unprecedented 11% across European NATO countries and Canada. Since 2014, the group has spent an additional US$600 billion on defence.
-
US Pentagon to reduce investments in main acquisition programmes over FY2025
The DoD requested nearly US$850 billion to fund operations over the next fiscal year. Despite the amount being 1% higher than the FY2024 budget request, it has not covered the 3% inflation rate, which could impact the DoD’s main programmes in the medium and long term.